睿知中国医院研究地图
候选清单

广州暨南大学

暨南大学附属第一医院

First Affiliated Hospital of Jinan University

在本站收录的 53 种疾病中,这家医院列在其中 18 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

暨南大学附属第一医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma16 篇牵头论文
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma5 篇牵头论文
  3. 肝细胞癌Hepatocellular carcinoma45 篇牵头论文牵头 1 项开放试验
  4. 胃癌Stomach cancer21 篇牵头论文
  5. 视网膜母细胞瘤Retinoblastoma0 篇牵头论文
  6. 骨肉瘤Osteosarcoma9 篇牵头论文
  7. 胃肠道间质瘤Gastrointestinal stromal tumour1 篇牵头论文
  8. 神经母细胞瘤Neuroblastoma2 篇牵头论文
  9. 多发性骨髓瘤Multiple myeloma5 篇牵头论文
  10. β 地中海贫血Beta thalassaemia2 篇牵头论文
  11. 重症肌无力Myasthenia gravis4 篇牵头论文
  12. 肝豆状核变性Wilson disease2 篇牵头论文
  13. 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis0 篇牵头论文
  14. 特发性肺纤维化Idiopathic pulmonary fibrosis1 篇牵头论文
  15. Alport 综合征Alport syndrome1 篇牵头论文
  16. IgA 肾病IgA nephropathy0 篇牵头论文
  17. 先天性巨结肠Hirschsprung disease2 篇牵头论文
  18. 遗传性大疱性表皮松解症Inherited epidermolysis bullosa2 篇牵头论文

未列出的收录疾病:肝母细胞瘤、脊索瘤、尤文肉瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、烟雾病、胆道闭锁、大动脉炎、肝包虫病、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、白塞病、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性膈疝、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 16 篇,占 0.7%。

牵头论文
16
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 4420212022: 3320222023: 5520232024: 1120242025: 222025

广州有 24 家医院列在鼻咽癌下全国有 183 家医院列在鼻咽癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的鼻咽癌开放试验。

这些数字背后的记录
研究主题影像与人工智能放疗技术EB病毒与筛查
论文中的科室影像/核医学科耳鼻喉/头颈外科病理/检验科肿瘤内科
牵头的论文16
  1. NPC-SurvAI: A fully automated deep learning framework for prognostic prediction and risk stratification in patients with nasopharyngeal carcinoma.2026Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  2. MRI-based model for individualized prediction of skull bone destruction and EBV DNA-related risk stratification in nasopharyngeal carcinoma patients.2025BMC medical imaging免费全文
  3. Retinoic acid enhances γδ T cell cytotoxicity in nasopharyngeal carcinoma by reversing immune exhaustion.2025Cell communication and signaling : CCS免费全文
  4. B7-H3 promotes nasopharyngeal carcinoma progression by regulating CD8+ T cell exhaustion.2024Immunity, inflammation and disease免费全文
  5. Early screening of nasopharyngeal carcinoma.2023Head & neck
  6. Integrative Scoring System for Survival Prediction in Patients With Locally Advanced Nasopharyngeal Carcinoma: A Retrospective Multicenter Study.2023JCO clinical cancer informatics
  7. Two web-based dynamically interactive nomograms and risk stratification systems for predicting survival outcomes and guiding treatment in non-metastatic nasopharyngeal carcinoma.2023Journal of cancer research and clinical oncologyRCT免费全文
  8. X-ray sensitive selenium-containing Ru complexes sensitize nasopharyngeal carcinoma cells for radio/chemotherapy.2023Journal of materials chemistry. B
  9. Prognostic significance of MRI-defined sarcopenia in patients with nasopharyngeal carcinoma: A propensity score matched analysis of real-world data.2023Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  10. The Dual-Targeted Peptide Conjugated Probe for Depicting Residual Nasopharyngeal Carcinoma and Guiding Surgery.2022Biosensors免费全文
  11. Carbonic anhydrase IX stratifies patient prognosis and identifies nodal status in animal models of nasopharyngeal carcinoma using a targeted imaging strategy.2022European journal of nuclear medicine and molecular imaging
  12. Identification of a five-miRNA signature as a novel potential prognostic biomarker in patients with nasopharyngeal carcinoma.2022Hereditas免费全文
  13. Concurrent chemoradiotherapy with additional chemotherapy for nasopharyngeal carcinoma: A pooled analysis of propensity score-matching studies.2021Head & neck
  14. MRI-Based Deep-Learning Model for Distant Metastasis-Free Survival in Locoregionally Advanced Nasopharyngeal Carcinoma.2021Journal of magnetic resonance imaging : JMRIRCT
  15. RE: A Prognostic Predictive System Based on Deep Learning for Locoregionally Advanced Nasopharyngeal Carcinoma.2021Journal of the National Cancer Institute免费全文
  16. High miR-3650 expression in nasopharyngeal carcinoma and its clinical prognostic values.2021Pathology, research and practice
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China状态不明NCT05638269研究中心2022-03 启动
PubMed 以外找到的论文(未计入)4
  1. Prognostic Value of Serum Lambda Free Light Chains in Nasopharyngeal Carcinoma2025Research Square预印本
  2. Dcalycinumines A—E, Alkaloids with Cytotoxic Activities of Nasopharyngeal Carcinoma Cells from Daphniphyllum calycinum2023Chinese Journal of Chemistry论文
  3. Surgical resection of the primary tumor improves survival in patients with locoregional stage T1 nasopharyngeal carcinoma: a propensity score-based matched analysis2023Research Square预印本
  4. Additional file 1 of A two-stage genome-wide association study to identify novel genetic loci associated with acute radiotherapy toxicity in nasopharyngeal carcinoma2022Figshare数据集

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.2%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 1120222023: 1120232024: 0020242025: 002025

广州有 11 家医院列在食管鳞状细胞癌下全国有 192 家医院列在食管鳞状细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。

这些数字背后的记录
研究主题影像与人工智能分子标志物与基因
论文中的科室普外/肝胆胰外科临床试验/研究机构

这些论文过半是实验室或动物研究。

牵头的论文5
  1. PTPRO suppresses lymph node metastasis of esophageal carcinoma by dephosphorylating MET.2023Cancer letters
  2. Generation and Application of Inducible Chimeric RNA ASTN2-PAPPAas Knockin Mouse Model.2022Cells免费全文
  3. Chimeric RNA ASTN2-PAPPAas aggravates tumor progression and metastasis in human esophageal cancer.2021Cancer letters
  4. Repurposing dextromethorphan and metformin for treating nicotine-induced cancer by directly targeting CHRNA7 to inhibit JAK2/STAT3/SOX2 signaling.2021Oncogene免费全文
  5. Nomogram based on immune scores for predicting the survival of patients with esophageal squamous cell carcinoma.2021The Journal of international medical research免费全文
PubMed 以外找到的论文(未计入)5
  1. Additional file 2 of FBXW7 loss of function promotes esophageal squamous cell carcinoma progression via elevating MAP4 and ERK phosphorylation2023Figshare数据集
  2. Additional file 1 of OTUB2 Regulates YAP1/TAZ to Promotes the Progression of Esophageal Squamous Cell Carcinoma2022Figshare数据集
  3. Additional file 7 of Heparanase is a prognostic biomarker independent of tumor purity and hypoxia based on bioinformatics and immunohistochemistry analysis of esophageal squamous cell carcinoma2022Figshare数据集
  4. Downregulation of long noncoding RNA breast cancer anti-estrogen resistance 4 inhibits cell proliferation, invasion, and migration in esophageal squamous cell carcinoma by regulating the microRNA-181c-5p/LIM and SH3 protein 1 axis2022Figshare数据集
  5. Sex Is Related to Overall Survival in Patients with Esophageal Squamous Cell Carcinoma: A Population-Based Study2021American Journal of Biomedical and Life Sciences论文

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 45 篇,占 0.3%。

牵头论文
45
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 7720212022: 7720222023: 9920232024: 101020242025: 11112025

广州有 15 家医院列在肝细胞癌下全国有 194 家医院列在肝细胞癌下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Two-Arm, Multicenter, Non-Randomized Controlled Study on the Efficacy of Yttrium-90 (Selective Internal Radiation Therapy) Therapy and Hepatic Arterial Infusion Chemotherapy (Hepatic Artery Infusion Chemotherapy) for Potentially Resectable Intermediate and Advanced Hepatocellular Carcinoma
    分期
    不分期
    开始
    2026-08
    登记号
    NCT07070076

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:暨南大学附属第一医院广州

  2. 正在招募
    MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.
    分期
    I期
    开始
    2025-08
    登记号
    NCT07391839

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 8 家列出的医院为研究中心上海、南京、合肥、广州、杭州、济南、福州、郑州

  3. 邀请入组
    Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China
    分期
    未注明
    开始
    2024-08
    登记号
    NCT06712017

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 4 家列出的医院为研究中心上海、北京、广州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题免疫与靶向药物局部治疗(消融、TACE、HAIC)影像、人工智能与早期发现
论文中的科室影像/核医学科消化/肝病科普外/肝胆胰外科肿瘤内科
牵头的论文45
  1. The diagnostic value of 18 F-FAPI-04 PET/CT in unresectable hepatocellular carcinoma: a head-to-head comparison with 18 F-FDG PET/CT.2026European journal of nuclear medicine and molecular imaging
  2. Effectiveness and Safety of TRIPLET Protocol in Patients with Intermediate-Stage Hepatocellular Carcinoma to Transcatheter Arterial Chemoembolization Refractory.2025Academic radiology
  3. MiRNA- 1293 Promotes Hepatocellular Carcinoma Cell Proliferation and Invasion by METTL3-Mediated m6 A Modification of Pri-miRNA- 1293.2025Applied biochemistry and biotechnology
  4. Analysis of risk factors for early mortality following hepatectomy in hepatocellular carcinoma patients.2025BMC surgery免费全文
  5. Copper-mediated SEC14L3 promotes cuproptosis to inhibit hepatocellular carcinoma growth via ERK/YY1/FDX1 axis.2025Communications biology免费全文
  6. PDHA1 Orchestrates Hepatocellular Carcinoma Progression Through LINC00607-Mediated Regulation of Cuproptosis and Immune Evasion.2025Digestive diseases and sciences
  7. Hepatic arterial infusion chemotherapy combined with lenvatinib and toripalimab for large hepatocellular carcinoma (> 10 cm) with major portal vein tumor thrombosis: a multicenter propensity score matching analysis.2025Frontiers in immunology免费全文
  8. Malectin, an endoplasmic reticulum-resident lectin, promotes malignant behavior of human hepatocellular carcinoma.2025Glycobiology
  9. Global Contribution of Drug Use to Cirrhosis and Hepatocellular Carcinoma Worldwide From 1990 to 2021 and Projections to 2045.2025Inquiry : a journal of medical care organization, provision and financing免费全文
  10. m6A Modification-Mediated Regulation of DCAF13 Promotes Glycolytic Metabolism and Drives Hepatocellular Carcinoma Progression via Interaction With G6PD.2025Journal of gastroenterology and hepatology
  11. Mir-483-5p-mediated activating of IGF2/H19 enhancer up-regulates IGF2/H19 expression via chromatin loops to promote the malignant progression of hepatocellular carcinoma.2025Molecular cancer免费全文
  12. Alterations of Nutrient Elements in Hepatocellular Carcinoma Patients Treated with Atezolizumab-Bevacizumab.2025Nutrition and cancer
  13. Efficiency and safety of hepatic arterial infusion chemotherapy (HAIC) combined with anti-PD1 therapy versus HAIC monotherapy for advanced hepatocellular carcinoma: A multicenter propensity score matching analysis.2024Cancer medicine免费全文
  14. Knockout of onecut2 inhibits proliferation and promotes apoptosis of tumor cells through SKP2-mediated p53 acetylation in hepatocellular carcinoma.2024Cellular and molecular life sciences : CMLS免费全文
  15. Case Report and Literature Review of Multi-drugs Synergy and Targeted Comprehensive Treatment in Advanced Hepatocellular Carcinoma.2024Current cancer drug targets
  16. Prognosis prediction and risk stratification of transarterial chemoembolization or intraarterial chemotherapy for unresectable hepatocellular carcinoma based on machine learning.2024European radiology免费全文
  17. Hepatic artery infusion chemotherapy combined with camrelizumab plus rivoceranib for hepatocellular carcinoma with portal vein tumor thrombosis: a multicenter propensity score-matching analysis.2024Hepatology international免费全文
  18. Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy.2024Journal for immunotherapy of cancer免费全文
  19. LINC00707 impairs the Natural Killer cell antitumour activity in hepatocellular carcinoma through decreasing YTHDF2 stability.2024Journal of cellular and molecular medicine免费全文
  20. GINS1 promotes ZEB1-mediated epithelial-mesenchymal transition and tumor metastasis via β-catenin signaling in hepatocellular carcinoma.2024Journal of cellular physiology
  21. Synergistic enhancement of low-dose radiation therapy via cuproptosis and metabolic reprogramming for radiosensitization in in situ hepatocellular carcinoma.2024Journal of nanobiotechnology免费全文
  22. An interpretable machine learning model based on contrast-enhanced CT parameters for predicting treatment response to conventional transarterial chemoembolization in patients with hepatocellular carcinoma.2024La Radiologia medica
  23. Hepatitis C virus nonstructural protein 4B induces lipogenesis via the Hippo pathway.2023Archives of virology免费全文
  24. Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and sequential ablation in the treatment of advanced hepatocellular carcinoma.2023Cancer medicine免费全文
  25. Identification of potential feature genes in non-alcoholic fatty liver disease using bioinformatics analysis and machine learning strategies.2023Computers in biology and medicine
  26. Deep learning nomogram based on Gd-EOB-DTPA MRI for predicting early recurrence in hepatocellular carcinoma after hepatectomy.2023European radiology免费全文
  27. FGFR4 and EZH2 inhibitors synergistically induce hepatocellular carcinoma apoptosis via repressing YAP signaling.2023Journal of experimental & clinical cancer research : CR免费全文
  28. Efficacy and safety of HAIC alone vs. HAIC combined with lenvatinib for treatment of advanced hepatocellular carcinoma.2023Medical oncology (Northwood, London, England)
  29. Polyphyllin D punctures hypertrophic lysosomes to reverse drug resistance of hepatocellular carcinoma by targeting acid sphingomyelinase.2023Molecular therapy : the journal of the American Society of Gene Therapy免费全文
  30. Clinical Features of Non-Alcoholic Fatty Liver Disease in the Non-Lean Population.2023Obesity facts免费全文
  31. Blockade of NMT1 enzymatic activity inhibits N-myristoylation of VILIP3 protein and suppresses liver cancer progression.2023Signal transduction and targeted therapy免费全文
  32. Real-time automatic prediction of treatment response to transcatheter arterial chemoembolization in patients with hepatocellular carcinoma using deep learning based on digital subtraction angiography videos.2022Cancer imaging : the official publication of the International Cancer Imaging Society免费全文
  33. NUSAP1, a novel stemness-related protein, promotes early recurrence of hepatocellular carcinoma.2022Cancer science免费全文
  34. Insulin-Like Growth Factor 1 Receptor Drives Hepatocellular Carcinoma Growth and Invasion by Activating Stat3-Midkine-Stat3 Loop.2022Digestive diseases and sciences
  35. FXYD5 promotes sorafenib resistance through the Akt/mTOR signaling pathway in hepatocellular carcinoma.2022European journal of pharmacology
  36. Hepatic arterial infusion chemotherapy and sequential ablation treatment in large hepatocellular carcinoma.2022International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  37. Design, Synthesis, and Biological Evaluation of 2-Formyl Tetrahydronaphthyridine Urea Derivatives as New Selective Covalently Reversible FGFR4 Inhibitors.2022Journal of medicinal chemistry
  38. ABI2-mediated MEOX2/KLF4-NANOG axis promotes liver cancer stem cell and drives tumour recurrence.2022Liver international : official journal of the International Association for the Study of the Liver免费全文
  39. Bioinformatics analysis of tumor-educated platelet microRNAs in patients with hepatocellular carcinoma.2021Bioscience reports免费全文
  40. LncRNA SNHG12 promotes proliferation and epithelial mesenchymal transition in hepatocellular carcinoma through targeting HEG1 via miR-516a-5p.2021Cellular signalling
  41. TANK-Binding Kinase 1 (TBK1) Serves as a Potential Target for Hepatocellular Carcinoma by Enhancing Tumor Immune Infiltration.2021Frontiers in immunology免费全文
  42. Upregulation of Stress-Induced Protein Kinase CK1 Delta is associated with a Poor Prognosis for patients with Hepatocellular Carcinoma.2021Genetic testing and molecular biomarkers
  43. Identification of hub genes associated with prognosis, diagnosis, immune infiltration and therapeutic drug in liver cancer by integrated analysis.2021Human genomics免费全文
  44. Comparative Analysis of Presentation and Outcome After Liver Resection of Patients With Hepatocellular Carcinoma With and Without HIV.2021Journal of acquired immune deficiency syndromes (1999)
  45. Deep Learning With 3D Convolutional Neural Network for Noninvasive Prediction of Microvascular Invasion in Hepatocellular Carcinoma.2021Journal of magnetic resonance imaging : JMRI
中文论文(未计入)1
  1. [Characteristics and treatment strategies for hepatocellular carcinoma caused by nonalcoholic fatty liver disease].2022Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
  1. A Two-Arm, Multicenter, Non-Randomized Controlled Study on the Efficacy of Yttrium-90 (Selective Internal Radiation Therapy) Therapy and Hepatic Arterial Infusion Chemotherapy (Hepatic Artery Infusion Chemotherapy) for Potentially Resectable Intermediate and Advanced Hepatocellular Carcinoma正在招募NCT07070076牵头方(推断)不分期2026-08 启动
  2. MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.正在招募NCT07391839研究中心I期2025-08 启动
  3. Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China邀请入组NCT06712017研究中心2024-08 启动
  4. Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere进行中,不再招募NCT06900543研究中心III期2025-04 启动
  5. Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular Carcinoma已完成NCT06310590研究中心I期2023-08 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 21 篇,占 0.2%。

牵头论文
21
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 6620212022: 6620222023: 2220232024: 2220242025: 552025

广州有 15 家医院列在胃癌下全国有 211 家医院列在胃癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的胃癌开放试验。

这些数字背后的记录
研究主题影像与人工智能腹膜转移与晚期手术
论文中的科室消化/肝病科影像/核医学科普外/肝胆胰外科临床试验/研究机构
牵头的论文21
  1. Combined protein and transcriptomics identifies DCTPP1 as a putative biomarkers for predicting immunotherapy responsiveness in gastric cancer patients.2025Anti-cancer drugs
  2. Transformer-based skeletal muscle deep-learning model for survival prediction in gastric cancer patients after curative resection.2025Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association免费全文
  3. The diagnostic and predictive value of LncRNA PANDAR in gastric cancer and its regulation of gastric cancer progression via miR-637.2025Hereditas免费全文
  4. A Transfer Learning Radiomics Nomogram to Predict the Postoperative Recurrence of Advanced Gastric Cancer.2025Journal of gastroenterology and hepatology
  5. Increasing miR-1260b predicts the risk of gastric cancer in atrophic gastritis patients and regulates cell growth and metastasis of gastric cancer.2025Revista espanola de enfermedades digestivas
  6. The Evaluation of Gastric Cancer Lymphovascular Invasion Using CT Volume Perfusion.2024Discovery medicine
  7. CircNRD1 elevates THAP domain containing 11 through sequestering microRNA-421 to inhibit gastric cancer growth and tumorigenesis.2024Journal of biochemical and molecular toxicology
  8. Relationship between histone demethylase LSD family and development and prognosis of gastric cancer.2023Frontiers in immunology免费全文
  9. The SMAD2/miR-4256/HDAC5/p16INK4a signaling axis contributes to gastric cancer progression.2023Oncology research免费全文
  10. Thrombospondin-2 holds prognostic value and is associated with metastasis and the mismatch repair process in gastric cancer.2022BMC cancer免费全文
  11. Recent Estimates and Predictions of 5-Year Survival in Patients with Gastric Cancer: A Model-Based Period Analysis.2022Cancer control : journal of the Moffitt Cancer Center免费全文
  12. Radiomics in precision medicine for gastric cancer: opportunities and challenges.2022European radiology
  13. Risk factors for gastric cancer: A comprehensive analysis of observational studies.2022Frontiers in public health免费全文
  14. Comprehensive Analysis of PDLIM3 Expression Profile, Prognostic Value, and Correlations with Immune Infiltrates in Gastric Cancer.2022Journal of immunology research免费全文
  15. Inhibition of apoptosis-regulatory protein Siva-1 reverses multidrug resistance in gastric cancer by targeting PCBP1.2022Oncology research免费全文
  16. Prevalence and characteristics of gastric remnant cancer: A systematic review and meta-analysis.2021Asian journal of surgery
  17. A survival comparison of gastric mucin-producing adenocarcinoma to conventional adenocarcinoma: a SEER database analysis.2021BMC cancer免费全文
  18. The diagnostic and clinicopathological value of trefoil factor 3 in patients with gastric cancer: a systematic review and meta-analysis.2021Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals
  19. A Novel Ferroptosis-Related Gene Risk Signature for Predicting Prognosis and Immunotherapy Response in Gastric Cancer.2021Disease markers免费全文
  20. The Upregulation of PLXDC2 Correlates with Immune Microenvironment Characteristics and Predicts Prognosis in Gastric Cancer.2021Disease markers免费全文
  21. Human Hyaluronidase PH20 Potentiates the Antitumor Activities of Mesothelin-Specific CAR-T Cells Against Gastric Cancer.2021Frontiers in immunology免费全文
中文论文(未计入)2
  1. [Onco-metabolic surgery: the bridge between curative resection of gastric cancer and the remission of type 2 diabetes mellitus].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  2. [Occurrence of gastric cancer after laparoscopic Roux-en-Y gastric bypass: a systematic review].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China状态不明NCT05638269研究中心2022-03 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

视网膜母细胞瘤

Retinoblastoma

2021–2025 年没有牵头视网膜母细胞瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

广州有 8 家医院列在视网膜母细胞瘤下全国有 176 家医院列在视网膜母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 9 篇,占 0.4%。

牵头论文
9
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 0020222023: 2220232024: 3320242025: 222025

广州有 30 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
论文中的科室影像/核医学科普外/肝胆胰外科

这些论文过半是实验室或动物研究。

牵头的论文9
  1. Pathology-interpretable radiomic model for predicting clinical outcome in patients with osteosarcoma: a retrospective, multicenter study.2025BMC medicine
  2. LncRNA OLMALINC promotes osteosarcoma progression through USP1-mediated autophagy suppression.2025Human cell
  3. METTL3/YTHDF1 stabilizes CORO6 expression promoting osteosarcoma progression through glycolysis.2024Experimental cell research
  4. Identification of UNC5B as a novel aggressive biomarker for osteosarcoma based on basement membrane genes.2024Gene
  5. HSPD1 Supports Osteosarcoma Progression through Stabilizing ATP5A1 and thus Activation of AKT/mTOR Signaling.2024International journal of biological sciences
  6. HSP90-regulated CHIP/TRIM21/p21 Axis Involves in the Senescence of Osteosarcoma Cells.2023Protein and peptide letters
  7. Comparing the diagnostic efficacy of [18F]FDG PET/CT and [18F]FDG PET/MRI for detecting bone metastases in breast cancer: a meta-analysis.2023Radiology and oncology
  8. TRIM21-regulated Annexin A2 plasma membrane trafficking facilitates osteosarcoma cell differentiation through the TFEB-mediated autophagy.2021Cell death & disease
  9. Notoginsenoside R1 counteracts mesenchymal stem cell-evoked oncogenesis and doxorubicin resistance in osteosarcoma cells by blocking IL-6 secretion-induced JAK2/STAT3 signaling.2021Investigational new drugs
早期论文(2016–2020 年)6
  1. PRMT5-TRIM21 interaction regulates the senescence of osteosarcoma cells by targeting the TXNIP/p21 axis.2020Aging
  2. HSP90 regulates osteosarcoma cell apoptosis by targeting the p53/TCF-1-mediated transcriptional network.2020Journal of cellular physiology
  3. Overexpression of TBL1XR1 confers tumorigenic capability and promotes recurrence of osteosarcoma.2019European journal of pharmacology
  4. Transcriptional regulation of Runx2 by HSP90 controls osteosarcoma apoptosis via the AKT/GSK-3β/β-catenin signaling.2018Journal of cellular biochemistry
  5. AHSA1 regulates proliferation, apoptosis, migration, and invasion of osteosarcoma.2016Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  6. [microRNA-181b promotes migration and invasion of osteosarcoma cells by targeting N-myc downstream regulated gene 2].2016Nan fang yi ke da xue xue bao = Journal of Southern Medical University

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.2%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

广州有 12 家医院列在胃肠道间质瘤下全国有 240 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.2%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

广州有 22 家医院列在神经母细胞瘤下全国有 321 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
论文中的科室消化/肝病科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.3%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 1120222023: 0020232024: 0020242025: 222025

广州有 14 家医院列在多发性骨髓瘤下全国有 175 家医院列在多发性骨髓瘤下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的多发性骨髓瘤开放试验。

这些数字背后的记录
研究主题双抗与抗体药物诊断、微小残留病与危险分层肾脏与骨骼并发症

打开 PubMed 检索ClinicalTrials.gov

血液疾病

β 地中海贫血

Beta thalassaemia

2021–2025 年中国大陆作者发表的 312 篇β 地中海贫血 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.6%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

广州有 18 家医院列在β 地中海贫血下全国有 133 家医院列在β 地中海贫血下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的β 地中海贫血开放试验。

这些数字背后的记录
牵头的论文2
  1. Effects of thalassemia minor on umbilical artery blood flow and perinatal outcomes in pregnancy: A retrospective cohort study.2025International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
  2. Prevalence and molecular characterization of common thalassemia among people of reproductive age in the border area of Guangxi-Yunnan-Guizhou province in Southwestern China.2022Hematology (Amsterdam, Netherlands)
早期论文(2016–2020 年)1
  1. Invasive prenatal diagnosis of fetal thalassemia.2017Best practice & research. Clinical obstetrics & gynaecology

打开 PubMed 检索ClinicalTrials.gov

其他疾病

重症肌无力

Myasthenia gravis

2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.8%。

牵头论文
4
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 1120242025: 222025

广州有 7 家医院列在重症肌无力下全国有 89 家医院列在重症肌无力下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的重症肌无力开放试验。

这些数字背后的记录
研究主题眼肌型重症肌无力抗体与诊断胸腺与胸腺切除
论文中的科室眼科/神经眼科神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肝豆状核变性

Wilson disease

2021–2025 年中国大陆作者发表的 201 篇肝豆状核变性 PubMed 英文论文中,这家医院牵头了 2 篇,占 1.0%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

广州有 5 家医院列在肝豆状核变性下全国有 28 家医院列在肝豆状核变性下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的肝豆状核变性开放试验。

这些数字背后的记录
研究主题遗传学(ATP7B)脑部与运动症状治疗(螯合剂、锌剂)
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

抗 NMDA 受体脑炎

Anti-NMDA receptor encephalitis

2021–2025 年没有牵头抗 NMDA 受体脑炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

广州有 12 家医院列在抗 NMDA 受体脑炎下全国有 124 家医院列在抗 NMDA 受体脑炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Clinical Evaluation of a Novel DAB Chromogenic Tissue-Based Assay for Detecting Anti-GABABR Antibodies即将招募NCT07858175研究中心2026-10 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

广州有 20 家医院列在特发性肺纤维化下全国有 288 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

Alport 综合征

Alport syndrome

2021–2025 年中国大陆作者发表的 58 篇Alport 综合征 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

广州有 5 家医院列在Alport 综合征下全国有 60 家医院列在Alport 综合征下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的Alport 综合征开放试验。

这些数字背后的记录
论文中的科室肾内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年没有牵头IgA 肾病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

广州有 16 家医院列在IgA 肾病下全国有 300 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

先天性巨结肠

Hirschsprung disease

2021–2025 年中国大陆作者发表的 161 篇先天性巨结肠 PubMed 英文论文中,这家医院牵头了 2 篇,占 1.2%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

广州有 8 家医院列在先天性巨结肠下全国有 76 家医院列在先天性巨结肠下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的先天性巨结肠开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

遗传性大疱性表皮松解症

Inherited epidermolysis bullosa

2021–2025 年中国大陆作者发表的 56 篇遗传性大疱性表皮松解症 PubMed 英文论文中,这家医院牵头了 2 篇,占 3.6%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

广州有 4 家医院列在遗传性大疱性表皮松解症下全国有 41 家医院列在遗传性大疱性表皮松解症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的遗传性大疱性表皮松解症开放试验。

这些数字背后的记录
牵头的论文2
  1. Two sisters with recessive dystrophic epidermolysis bullosa caused by novel variants in COL7A1.2024Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)
  2. Highly branched poly(β-amino ester)s for gene delivery in hereditary skin diseases.2021Advanced drug delivery reviews

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

暨南大学附属第一医院

First Affiliated Hospital of Jinan University

广州

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
first affiliated hospital of Jinan University; Guangzhou Overseas Chinese Hospital

提出更正下载数据